Taken together, our findings have clinical implications for breast cancer and potentially many other cancers where FOXM1/pMAPK signaling pathways are active, and make a case for the use of FOXM1 inhibitors in combination with current therapies, including protein kinase inhibitors, to improve effectiveness and long-term patient response to treatments. This evidence concerns the gene WEE1 and breast carcinoma.